These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22846092)

  • 21. Treatment of ocular disorders by gene therapy.
    Solinís MÁ; del Pozo-Rodríguez A; Apaolaza PS; Rodríguez-Gascón A
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):331-42. PubMed ID: 25536112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Ocular Gene Delivery Landscape.
    Sahu B; Chug I; Khanna H
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical applications of retinal gene therapy.
    Lipinski DM; Thake M; MacLaren RE
    Prog Retin Eye Res; 2013 Jan; 32():22-47. PubMed ID: 22995954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current nanotechnological strategies for treating glaucoma.
    Goyal G; Garg T; Rath G; Goyal AK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(5):365-405. PubMed ID: 25271557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An agonistic TrkB mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma.
    Bai Y; Xu J; Brahimi F; Zhuo Y; Sarunic MV; Saragovi HU
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4722-31. PubMed ID: 20357199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene delivery to the retina: focus on non-viral approaches.
    Naik R; Mukhopadhyay A; Ganguli M
    Drug Discov Today; 2009 Mar; 14(5-6):306-15. PubMed ID: 18973824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Light at the end of the tunnel? Advances in the understanding and treatment of glaucoma and inherited retinal degeneration.
    Ofri R; Narfström K
    Vet J; 2007 Jul; 174(1):10-22. PubMed ID: 17307370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic applications of ultrasound in ophthalmology.
    Aptel F; Lafon C
    Int J Hyperthermia; 2012; 28(4):405-18. PubMed ID: 22621741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanotechnology approaches for ocular drug delivery.
    Xu Q; Kambhampati SP; Kannan RM
    Middle East Afr J Ophthalmol; 2013; 20(1):26-37. PubMed ID: 23580849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.
    Tawfik M; Chen F; Goldberg JL; Sabel BA
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Dec; 395(12):1477-1507. PubMed ID: 36107200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of microbubbles to target drug delivery.
    Tsutsui JM; Xie F; Porter RT
    Cardiovasc Ultrasound; 2004 Nov; 2():23. PubMed ID: 15546496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanomaterials for ocular drug delivery.
    Liu S; Jones L; Gu FX
    Macromol Biosci; 2012 May; 12(5):608-20. PubMed ID: 22508445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glaucoma: genes, phenotypes, and new directions for therapy.
    Fan BJ; Wiggs JL
    J Clin Invest; 2010 Sep; 120(9):3064-72. PubMed ID: 20811162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities.
    El Hoffy NM; Abdel Azim EA; Hathout RM; Fouly MA; Elkheshen SA
    Eur J Pharm Sci; 2021 Mar; 158():105648. PubMed ID: 33227347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters.
    Attar M; Shen J; Ling KH; Tang-Liu D
    Expert Opin Drug Deliv; 2005 Sep; 2(5):891-908. PubMed ID: 16296785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential of stem cell research for the treatment of neuronal damage in glaucoma.
    Karl MO
    Cell Tissue Res; 2013 Aug; 353(2):311-25. PubMed ID: 23708526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and obstacles of ocular pharmacokinetics and drug delivery.
    Urtti A
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1131-5. PubMed ID: 17097758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers and special features of oxidative stress in the anterior segment of the eye linked to lens cataract and the trabecular meshwork injury in primary open-angle glaucoma: challenges of dual combination therapy with N-acetylcarnosine lubricant eye drops and oral formulation of nonhydrolyzed carnosine.
    Babizhayev MA
    Fundam Clin Pharmacol; 2012 Feb; 26(1):86-117. PubMed ID: 21883446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.